Norge -
norsk -
Statens legemiddelverk
calcigran forte 1000 mg / 800 ie
2care4 aps - kalsiumkarbonat / kolekalsiferol - tyggetablett - 1000 mg / 800 ie
Norge -
norsk -
Statens legemiddelverk
calcigran forte 1000 mg / 800 ie
2care4 aps - kalsiumkarbonat / kolekalsiferol - tyggetablett - 1000 mg / 800 ie
Norge -
norsk -
Statens legemiddelverk
calcigran forte 1000 mg / 800 ie
2care4 aps - kalsiumkarbonat / kolekalsiferol - tyggetablett - 1000 mg / 800 ie
Norge -
norsk -
Statens legemiddelverk
calcigran forte 1000 mg / 800 ie
2care4 - kalsiumkarbonat / kolekalsiferol - tyggetablett - 1000 mg / 800 ie
Norge -
norsk -
Statens legemiddelverk
calcigran forte 1000 mg / 800 ie
paranova as - kalsiumkarbonat / kolekalsiferol - tyggetablett - 1000 mg / 800 ie
Norge -
norsk -
Statens legemiddelverk
rocaltrol 0.25 mikrog
atnahs pharma netherlands b.v. - kalsitriol - kapsel, myk - 0.25 mikrog
Norge -
norsk -
Statens legemiddelverk
rocaltrol 0.25 mikrog
2care4 aps - kalsitriol - kapsel, myk - 0.25 mikrog
Norge -
norsk -
Statens legemiddelverk
rocaltrol 0.25 mikrog
2care4 aps - kalsitriol - kapsel, myk - 0.25 mikrog
Norge -
norsk -
Statens legemiddelverk
rocaltrol 0.25 mikrog
2care4 aps - kalsitriol - kapsel, myk - 0.25 mikrog
Den europeiske union -
norsk -
EMA (European Medicines Agency)
crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - legemidler til behandling av bein sykdommer - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.